Structure-activity relationships for NAMI-A-type complexes (HL)[trans-RuCl4L(S-dmso)ruthenate(III)] (L = imidazole, indazole, 1,2,4-triazole, 4-amino-1,2,4-triazole, and 1-methyl-1,2,4-triazole): aquation, redox properties, protein binding, and anti
about
Ru-TAP complexes and DNA: from photo-induced electron transfer to gene photo-silencing in living cellsRuthenium metalation of proteins: the X-ray structure of the complex formed between NAMI-A and hen egg white lysozymeUnusual mode of protein binding by a cytotoxic π-arene ruthenium(ii) piano-stool compound containing an O,S-chelating ligandKinetic and mechanistic studies on reactions of diruthenium(II,III) with biologically relevant reducing agents.Microwave synthesis of mixed ligand diimine-thiosemicarbazone complexes of ruthenium(II): biophysical reactivity and cytotoxicity.Transferring the concept of multinuclearity to ruthenium complexes for improvement of anticancer activity.Impact of low- and high-molecular-mass components of human serum on NAMI-A binding to transferrin.Organometallic ruthenium complexes with thiosemicarbazone ligands: Synthesis, structure and cytotoxicity of [(eta-p-cymene)Ru(NS)Cl] (NS = 9-anthraldehyde thiosemicarbazones).Hypoxia-selective inhibition of angiogenesis development by NAMI-A analogues.Antiproliferative effects of ruthenium-based nucleolipidic nanoaggregates in human models of breast cancer in vitro: insights into their mode of action.Capillary electrophoretic methods in the development of metal-based therapeutics and diagnostics: new methodology and applications.Application of mass spectrometric techniques to delineate the modes-of-action of anticancer metallodrugs.Lipophilicity-dependent ruthenium N-heterocyclic carbene complexes as potential anticancer agents.X-ray fluorescence imaging of single human cancer cells reveals that the N-heterocyclic ligands of iodinated analogues of ruthenium anticancer drugs remain coordinated after cellular uptake.Cellular uptake mechanisms of an antitumor ruthenium compound: the endosomal/lysosomal system as a target for anticancer metal-based drugs.Synthesis, characterization and antitumor properties of two highly cytotoxic ruthenium(iii) complexes with bulky triazolopyrimidine ligands.Structure-activity relationships for organometallic osmium arene phenylazopyridine complexes with potent anticancer activity.Addition of ethynylferrocene to transition-metal complexes containing a chelating 1,2-dicarba-closo-dodecaborane-1,2-dichalcogenolate ligand--in vitro cooperativity of a ruthenium compound on cellular uptake of an anticancer drug.In vitro anticancer activity and biologically relevant metabolization of organometallic ruthenium complexes with carbohydrate-based ligands.Albumin binding and ligand-exchange processes of the Ru(III) anticancer agent NAMI-A and its bis-DMSO analogue determined by ENDOR spectroscopy.The first example of MEEKC-ICP-MS coupling and its application for the analysis of anticancer platinum complexes.Modulating the activity of short arginine-tryptophan containing antibacterial peptides with N-terminal metallocenoyl groups.Physicochemical Studies and Anticancer Potency of Ruthenium η-p-Cymene Complexes Containing Antibacterial QuinolonesHistone-deacetylase-targeted fluorescent ruthenium(II) polypyridyl complexes as potent anticancer agents.Structure-activity relationships for ruthenium and osmium anticancer agents - towards clinical development.A hypoxia efficient imidazole-based Ru(II) arene anticancer agent resistant to deactivation by glutathione.New [(η(5)-C5H5)Ru(N-N)(PPh3)][PF6] compounds: colon anticancer activity and GLUT-mediated cellular uptake of carbohydrate-appended complexes.Aquation Is a Crucial Activation Step for Anticancer Action of Ruthenium(II) Polypyridyl Complexes to Trigger Cancer Cell Apoptosis.Anticancer activity of structurally related ruthenium(II) cyclopentadienyl complexesImidazoles as potential anticancer agents
P2860
Q27014967-F867A441-21E1-4165-94F7-CD0634E897B7Q27689147-35E965A9-CEE0-4416-AF62-7B520BDEEA19Q27720200-D82AC21F-96C2-46CE-970F-D545E888C4EBQ30670864-602884DF-60DE-4EF9-B032-040AE12250CCQ33621824-A89E63AD-6523-4F1C-885C-8F5020C93925Q33640724-0286F8DF-BA1E-4602-ADEA-0E204CE695ADQ35621511-369C6549-FDAD-489C-BE86-D4D0CF671ACCQ37402859-050F7507-3141-4BBE-B1D5-EC31665F65E8Q37424157-7C0E2448-E4B7-4554-8212-86DB9211DB7EQ37724010-DB11FA38-A681-4D2C-A9D1-38160A1515ACQ37997361-96906BC1-468F-4F97-AD8B-98FD9B3B1A4EQ38105454-26E486D4-AC93-4C11-A906-97F5041C3B9FQ38896547-C2C9D680-3A7D-4D32-8FBB-6BCB8CA1103EQ39110547-63C5FBFD-9C07-4295-89B6-5BD1ABDD2059Q39136843-1929D887-B34F-4F2A-8335-F35A1F482DADQ39208851-5254E880-F9A7-4435-92EB-B5250E54B7CDQ39485992-2D30C393-2105-4F99-9E27-C1E3F13E679EQ39904369-F54B290A-A67A-46E6-ABE0-6E52B4C55796Q39952629-EFF360B6-9F4E-45A0-BCC2-433D28E3025CQ40737623-7EB8A993-6F45-4CF5-B7F1-699AF70F366CQ41770357-82A43A52-94DF-4A58-94C9-89E9BC3388B3Q42373851-6301B33B-D3ED-4DE9-869B-EF08AD58E450Q42725980-AEE4D81F-4F66-43BC-8948-36B36426C7AFQ46157208-F7CF2C6C-93DE-42B2-B8C4-410CFE8D1504Q49687144-80CF684C-C41B-4089-9DAA-45C26F33F3F4Q51652789-1FA3B7DB-F2FF-4FA7-BFEC-E029FA947D2AQ53095820-411E6B56-3FBC-4E1C-BE7D-3764A8C0F6CCQ53463488-349B3228-51B8-4B4C-A9B0-E5A6EDCE6844Q59082814-66D4608E-A7B5-4B06-AC6C-A714DDBB549DQ59149996-0A3844A3-AFD2-4023-828F-84A73B28F095
P2860
Structure-activity relationships for NAMI-A-type complexes (HL)[trans-RuCl4L(S-dmso)ruthenate(III)] (L = imidazole, indazole, 1,2,4-triazole, 4-amino-1,2,4-triazole, and 1-methyl-1,2,4-triazole): aquation, redox properties, protein binding, and anti
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Structure-activity relationshi ...... ies, protein binding, and anti
@en
type
label
Structure-activity relationshi ...... ies, protein binding, and anti
@en
prefLabel
Structure-activity relationshi ...... ies, protein binding, and anti
@en
P2093
P50
P356
P1476
Structure-activity relationshi ...... ies, protein binding, and anti
@en
P2093
Andrei R Timerbaev
Erwin Reisner
Rene Eichinger
Vladimir B Arion
P304
P356
10.1021/JM061081Y
P407
P577
2007-04-03T00:00:00Z